Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows in line with its trailing trend
Q2 FY2026 revenue of $796.2M rose 9.9% year over year, ahead of the +9.3% change in trailing-twelve-month revenue. Sequentially, it rose 10.2% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $3.21B (+6.4%) for the fiscal year ending Dec 2026, a slowdown from the +8.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $796.2M+10.2% QoQ
- Last fiscal yearDec 2025
- $3.02B+8.0% YoY
- LTMJun 2026
- $3.12B+9.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.9% | +4.2% | -5.7 pp |
| 1 year | +8.0% | +6.4% | -1.7 pp |
| 3-year CAGR | +10.9% | +8.7% | -2.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 3.02B USD
- Year-over-year change
- +8.0%
- 4-year CAGR
- +9.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.02B | +8.0% |
| FY2024 | 2024-12-31 | 2.79B | +16.7% |
| FY2023 | 2023-12-31 | 2.39B | +8.2% |
| FY2022 | 2022-12-31 | 2.21B | +5.7% |
| FY2021 | 2021-12-31 | 2.09B | — |
Revenue vs competitors
How AMRX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +9.3% is the 4th highest of 11, against a peer median of +3.1%.
- Over three fiscal years its annual growth of +10.9% compares with a peer median of +6.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | ₹331.38B INR | -3.1% | +12.9% | |
| LTM Jun 2026 | $17.31B USD | +4.1% | +5.0% | |
| LTM Jun 2026 | $14.74B USD | +4.4% | -4.2% | |
| LTM Jun 2026 | $10.85B USD | +10.1% | +8.1% | |
| LTM Jun 2026 | $4.14B USD | -4.2% | -1.5% | |
| LTM Jun 2026 | $3.12B USD | +9.3% | +10.9% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $1.33B USD | +13.5% | +11.2% |
| LTM Mar 2026 | $923.71M USD | +37.0% | +40.8% | |
| LTM Mar 2026 | $720.53M USD | -1.1% | +13.0% | |
| LTM Mar 2026 | $676.8M USD | -29.9% | -12.7% | |
| LTM Mar 2026 | $41.94M USD | +2.1% | +2.0% | |
| Peer median (excluding AMRX) | — | +3.1% | +6.5% | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B |
| Cost of Revenue | 1.32B | 1.42B | 1.53B | 1.77B | 1.88B |
| Gross Profit | 768.97M | 791.46M | 863.87M | 1.02B | 1.14B |
| Gross Margin | 36.7% | 35.8% | 36.1% | 36.5% | 37.6% |
| Research & Development | 209.56M | 208.66M | 194.75M | 190.71M | 186.18M |
| Selling, General & Admin | 365.5M | 399.7M | 429.68M | 476.44M | 526.83M |
| Operating Expenses | 616.26M | 886.39M | 659.5M | 771.11M | 713M |
| Depreciation & Amortization | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
| EBITDA | 401.1M | 440.21M | 500.78M | 439.77M | 603.87M |
| EBITDA Margin | 19.2% | 19.9% | 20.9% | 15.7% | 20.0% |
| Operating Income | 152.72M | (94.93M) | 204.37M | 249.33M | 423.09M |
| Operating Margin | 7.3% | -4.3% | 8.5% | 8.9% | 14.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 136.33M | 158.38M | 210.63M | 258.6M | 241.09M |
| Other Income / Expenses | (121.35M) | (153.2M) | (244.64M) | (304.34M) | (283.88M) |
| Income Before Tax | 31.37M | (248.13M) | (40.27M) | (55.01M) | 139.21M |
| Pre-Tax Margin | 1.5% | -11.2% | -1.7% | -2.0% | 4.6% |
| Income Tax Expense | 11.2M | 6.66M | 8.45M | 18.86M | 11.28M |
| Net Income | 10.62M | (129.99M) | (83.99M) | (116.89M) | 72.06M |
| Net Margin | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% |
| EPS (Basic) | 0.07 | (0.86) | (0.48) | (0.38) | 0.23 |
| EPS (Diluted) | 0.07 | (0.86) | (0.48) | (0.38) | 0.22 |
| Weighted Avg Shares | 148.92M | 150.94M | 174.99M | 308.98M | 313.37M |
| Weighted Avg Shares (Diluted) | 151.82M | 150.94M | 176.14M | 308.98M | 324.81M |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.